Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA-OK'd and launched in 2023.